-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, P2t+tld/JUnhs5r38lYvkD2lir1GBPs3e6EG5gN7D8ksZIp28nFkyYUL8udeQ2ug kR62lqAylSxCn+NvOP6ckg== 0000912057-96-013814.txt : 19960705 0000912057-96-013814.hdr.sgml : 19960705 ACCESSION NUMBER: 0000912057-96-013814 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19960331 FILED AS OF DATE: 19960703 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARRIS PHARMACEUTICAL CORP/DE/ CENTRAL INDEX KEY: 0000913056 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222969941 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-22788 FILM NUMBER: 96590808 BUSINESS ADDRESS: STREET 1: 385 OYSTER POINT BLVD STREET 2: SUITE 3 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 4157378600 MAIL ADDRESS: STREET 1: 385 OYSTER POINT BLVD STREET 2: SUITE 3 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 10-Q/A 1 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A AMENDMENT NO. 1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 1996 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 0-22788 ARRIS PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 22-2969941 - -------------------------------------------------------------------------------- (State or other jurisdiction (I.R.S. Employer Identification No.) of incorporation or organization) 385 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CALIFORNIA 94080 (Address of principal executive offices including zip code) (415) 829-1000 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No. The number of outstanding shares of the registrant's Common Stock, $0.001 par value, was 13,992,805 as of April 30, 1996. ARRIS PHARMACEUTICAL CORPORATION INDEX PAGE NUMBER ----------- PART II. OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K. 3 SIGNATURES 4 2 PART II. OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K. (a) Exhibits Item Description ---- ----------- 10.33* Amendment to Agreement dated March 29, 1993 between the Registrant and Kabi Pharmacia AB, dated January 31, 1996. (1) 10.34* First Amendment to Research and License Agreement dated May 28, 1993 between Registrant and Amgen, Inc., dated February 2, 1996. (1) 10.35* Research Agreement between the Registrant and Pharmacia & Upjohn, Inc., a Delaware corporation, dated February 29, 1996. (1) 10.36* Form of Sixth Amendment to Lease dated October 15, 1992 between the Registrant and Shelton Properties, Inc. dated March 27, 1996. 10.37* Financing Agreement between Hambrecht and Quist Guaranty Finance, LLC, dated March 29, 1996, including Security Agreement and Warrant Purchase Agreement of even date. 10.38* Amendment to Lease Schedule under Master Property Lease Agreement dated March 29, 1994 between Hambrecht and Quist Guaranty Finance, L.P., dated March 29, 1996. 27 Financial Data Schedule * Previously filed (1) Confidential treatment has been requested for portions to this document. Brackets indicate portions of text that have been omitted. A separate filing of such omitted text has been made with the Commission as part of the Company's application for confidential treatment. (b) Reports on Form 8-K A Current Report on Form 8-K was filed on January 5, 1996, as amended on February 5, 1996 to include financial statements and pro forma financial information, in conjunction with the Company's acquisition of Khepri Pharmaceuticals, Inc., which was completed on December 22, 1995. 3 ARRIS PHARMACEUTICAL CORPORATION SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed in its behalf by the undersigned thereunto duly authorized. ARRIS PHARMACEUTICAL CORPORATION Date: July 2, 1996 By: /s/ John P. Walker -------------------------------------- John P. Walker President, Chief Executive Officer and Director Date: July 2, 1996 By: /s/ Daniel H. Petree -------------------------------------- Daniel H. Petree Vice President, Corporate Development Chief Financial Officer 4 ARRIS PHARMACEUTICAL CORPORATION INDEX OF EXHIBITS 10.33* Amendment to Agreement dated March 29, 1993 between the Registrant and Kabi Pharmacia AB, dated January 31, 1996. (1) 10.34* First Amendment to Research and License Agreement dated May 28, 1993 between Registrant and Amgen, Inc., dated February 2, 1996. (1) 10.35* Research Agreement between the Registrant and Pharmacia & Upjohn, Inc., a Delaware corporation, dated February 29, 1996. (1) 10.36* Form of Sixth Amendment to Lease dated October 15, 1992 between the Registrant and Shelton Properties, Inc. dated March 27, 1996. 10.37* Financing Agreement between Hambrecht and Quist Guaranty Finance, LLC, dated March 29, 1996, including Security Agreement and Warrant Purchase Agreement of even date. 10.38* Amendment to Lease Schedule under Master Property Lease Agreement dated March 29, 1994 between Hambrecht and Quist Guaranty Finance, L.P., dated March 29, 1996. 27 Financial Data Schedule * Previously filed (1) Confidential treatment has been requested for portions to this document. Brackets indicate portions of text that have been omitted. A separate filing of such omitted text has been made with the Commission as part of the Company's application for confidential treatment. 5 EX-27 2 FINANCIAL DATA SCHEDULE
5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONSOLIDATED BALANCE SHEETS, STATEMENTS OF OPERATIONS AND STATEMENTS OF CASH FLOWS INCLUDED IN THE COMPANY'S FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS AND NOTES THERETO. 1,000 3-MOS DEC-31-1996 JAN-01-1996 MAR-31-1996 48,127 18,256 0 0 0 67,849 17,696 9,612 76,841 16,514 4,051 0 0 13,333 42,574 76,841 0 5,044 0 5,644 1,205 0 115 (1,563) 0 (1,563) 0 0 0 (1,563) (.15) (.15)
-----END PRIVACY-ENHANCED MESSAGE-----